How have the shares performed?
Regulus Therapeutics Inc. (RGLS) saw downtrend of -19.42% in the recent trading with $1.12 being its most recent. The current price level -51.72% lower than the highest price of $2.32 marked by the stock while trading over the past 52-weeks, whereas it is 165.28% higher than the lowest price of $0.42 the company dropped to over past 52-weeks. The latest news story on RGLS appeared in Benzinga under the title “Regulus Therapeutics’ RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study” on May-03-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -31.29% below one month high and is +8.74% above of the lowest during that time. Looking into the simple moving average, Regulus Therapeutics Inc. (RGLS)’s stock stands at a SMA-50 of $1.4612 while that of 5-day is reading $1.3960.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and RGLS’s SMA-200 as of now is $1.0052.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Hold by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 3.00 for the stock.
Regulus Therapeutics Inc. Earnings – What Happened With RGLS
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Regulus Therapeutics Inc. (RGLS) last released financial results for the quarter that ended 12/30/2020, posting a surprise factor of 78.60% for net revenue. During the reported three-month period, company’s sales were $5.0 billion while analysts on average were estimating the same to be $20000.0.
RGLS – Regulus Therapeutics Inc. Stock Earnings Estimates
The perspective of Regulus Therapeutics Inc. (NASDAQ:RGLS)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.14 for stock’s EPS in the current quarter. 2 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -0.03.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 47.82 million. RGLS does have institutional investors; and they hold 57.10% of the stock.
Regulus Therapeutics Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 75,850 shares. On the other hand, RGLS declared 11,942 shares have been sold in 4 insider transactions over the past three months.
As on Dec 30, 2020, NEA Management Company, LLC was the top most holder in Regulus Therapeutics Inc. (NASDAQ:RGLS) with an ownership of 6.45 million shares of the company or 8.62% of the stake worth $8.71 million. The filing also reveals BVF Inc. as the second largest holder in the company with a control over 4.51% of the outstanding shares. Its stake is worth $4.56 million for having 3.38 million shares in hand.
Point72 Asset Management, L.P. also came holding a key position in the company during the recent quarter and it now holds 4.30% of the outstanding shares. With this there are now 37 institutions which have possession in RGLS’s shares.
Currently, the stock has been recommended as Hold by 2 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 3.00 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Regulus Therapeutics Inc. was 2.89 while posting a debt to equity ratio of 0.18.
Regulus Therapeutics Inc.’s return on equity, or ROE, is -109.90%, compared to the industry average of -44.41% for Healthcare – Biotechnology. Although this indicates that RGLS fails to use its equity well, the metric will vary significantly depending on the industry.